H.C. Wainwright raised the firm’s price target on Genmab (GMAB) to $36 from $35 and keeps a Buy rating on the shares following the Q2 report. The ...

European shares hit a near two-week high on Wednesday, underpinned by gains in heavyweight healthcare and technology stocks, ...

Genmab has announced that its phase 3 EPCORE FL-1 trial met both primary endpoints in patients with relapsed or refractory ...

Genmab ( ($GMAB) ) has issued an update. On August 12, 2025, Genmab A/S announced a capital increase of 4,563 shares following the exercise of ...

Genmab A/S (NASDAQ:GMAB) is one of the top most undervalued biotech stocks to buy now. On August 7, William Blair analyst ...

The promising results, along with a separate FDA decision, could signal a major expansion of the use of the two companies' ...